https://www.avient.com/sites/default/files/2022-09/Avient Pro Forma Financial Information.pdf
They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; including recessionary conditions • The current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows • Changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; • Fluctuations in raw material prices, quality and supply, and in energy prices and supply; • Production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • An inability to raise or sustain prices for products or services; • Our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; • Information systems failures and cyberattacks; • Amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; • The ability to obtain required regulatory approvals and otherwise consummate the proposed sales of the Distribution business; and • Other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation and any recessionary conditions Use of Non-GAAP Measures This presentation includes the use of both GAAP (generally accepted accounting principles) and non-GAAP financial measures. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 PRO FORMA 2021 TO 2022 BRIDGE 3 2021 EPS from Continuing Operations 1.69$ Pro Forma & Special Items 1.33 Proforma 2021 Adjusted EPS 3.02$ FX Impact (0.22) China Lockdowns / Russia Import Sales (0.24) Outdoor High Performance (0.13) Dyneema 0.06 Color, Additives and Inks 0.38 Legacy Specialty Engineered Materials 0.22 Other 0.01 Proforma 2022 Adjusted EPS 3.10$ COLOR, ADDITIVES AND INKS 7% (4%) (9%) 6% (10%) 0% 1% 2% 7% 10% 4% (3%) 12% (6%) 5% 6% 9% 610 650 624 649 587 565 581 526 2,402 2,390 589 650 589 649 543 565 545 526 2,266 2,390 116 121 112 119 93 95 88 79 409 414 113 121 106 119 87 95 84 79 390 414 10% 4 (1%) PRO FORMA SPECIALTY ENGINEERED MATERIALS 16%8% (8%) (8%) 3% (6%) (6%) (2%) 2% 20%12% (1%) (2%) 5% (1%) (2%) 3% 6% 314 338 348 343 325 300 321 295 1,308 1,276 303 338 329 343 303 300 301 295 1,236 1,276 67 78 75 77 70 66 66 62 278 283 65 78 73 77 67 66 63 62 268 283 5 Constant Currency Adjusted EPS Adjusted EPS PRO FORMA AVIENT 10% (3%) (21%) 3% 9% 5% 7% (5%) (9%) (1%) (1%) (12%) 1% 17% 8% (14%) 11% 14% 10% 11% 2% (3%) 5% 8% (5%) 7% 925 987 973 992 912 867 902 823 3,712 3,669 893 987 919 992 847 867 845 823 3,504 3,669 161 176 164 172 142 141 133 117 600 606 155 176 157 172 131 141 123 117 566 6068% 2% 0.84 0.98 0.87 0.96 0.70 0.68 0.61 0.48 3.02 3.10 0.79 0.98 0.82 0.96 0.63 0.68 0.56 0.48 2.80 3.10 17% 24% 6 2022年3月31日 2021年3月31日 Net income from continuing operations $ 64.7 $ 60.4 Net income attributable to noncontrolling interests (0.3) (0.4) Net income from continuing operations attributable to Avient shareholders $ 64.4 $ 0.70 $ 60.0 $ 0.65 Special items, after tax $ 6.4 $ 0.07 $ 2.6 $ 0.03 APM pro forma adjustments 2.6 0.03 (3.1) (0.03) Amortization expense, after tax 17.4 0.19 17.9 0.19 Adjusted pro forma net income / EPS $ 90.8 $ 0.98 $ 77.4 $ 0.84 Weighted average diluted shares 92.3 92.2 2022年6月30日 2021年6月30日 Net income from continuing operations $ 62.8 $ 50.2 Net income attributable to noncontrolling interests — (0.6) Net income from continuing operations attributable to Avient shareholders $ 62.8 $ 0.68 $ 49.6 $ 0.54 Special items, after tax $ 3.2 $ 0.03 $ 11.7 $ 0.13 APM pro forma adjustments 5.2 0.06 1.4 0.02 Amortization expense, after tax 17.2 0.19 17.8 0.19 Adjusted pro forma net income / EPS $ 88.4 $ 0.96 $ 80.5 $ 0.87 Weighted average diluted shares 92.1 92.4 2021年9月30日 Reconciliation to Condensed Consolidated Statements of Income Avient EPS Net income from continuing operations $ 33.4 Net income attributable to noncontrolling interests 0.3 Net income from continuing operations attributable to Avient shareholders $ 33.7 $ 0.37 Special items, after tax $ 11.7 $ 0.13 APM pro forma adjustments 1.5 0.02 Amortization expense, after tax 17.6 0.19 Adjusted pro forma net income / EPS $ 64.5 $ 0.70 Weighted average diluted shares 92.2 Adjusted EPS may not recalculate due to rounding. 1 2021年12月31日 Year Ended 2021年12月31日 Net income from continuing operations $ 11.2 $ 155.2 Net income attributable to noncontrolling interests 0.9 0.2 Net income from continuing operations attributable to Avient shareholders $ 12.1 $ 0.13 $ 155.4 $ 1.69 Special items, after tax $ 24.0 $ 0.26 $ 50.0 $ 0.54 APM pro forma adjustments 2.5 0.03 1.6 0.02 Amortization expense, after tax 17.8 0.19 71.1 0.77 Adjusted pro forma net income / EPS $ 56.4 $ 0.61 $ 278.1 $ 3.02 Weighted average diluted shares 92.4 92.1 Reconciliation of Color, Additives and Inks EBITDA Operating Income 88.8 86.3 66.8 61.2 303.1 94.5 93.6 Depreciation and amortization 27.4 25.3 26.6 26.4 105.7 26.0 25.9 EBITDA $ 116.2 $ 111.6 $ 93.4 $ 87.6 $ 408.8 $ 120.5 $ 119.5 Q1 2021 Q2 2021 Q3 2021 Pro forma Pro forma Pro forma Pro forma Pro forma Pro forma Operating Income 32.6 9.1 41.7 35.8 13.9 49.7 30.0 15.2 45.2 Depreciation and amortization 7.8 17.5 25.3 8.1 17.3 25.4 7.9 17.1 25.0 EBITDA $ 40.4 $ 26.6 $ 67.0 $ 43.9 $ 31.2 $ 75.1 $ 37.9 $ 32.3 $ 70.2 Q4 2021 YTD 2021 Pro forma Pro forma Pro forma Pro forma Operating Income 27.1 11.7 38.8 125.5 49.9 175.4 Depreciation and amortization 8.0 18.9 26.9 31.8 70.8 102.6 EBITDA $ 35.1 $ 30.6 $ 65.7 $ 157.3 $ 120.7 $ 278.0 2 Q1 2022 Q2 2022 Pro forma Pro forma Pro forma Pro forma Operating Income 38.3 15.4 53.7 35.2 17.7 52.9 Depreciation and amortization 7.8 16.6 24.4 7.7 16.6 24.3 EBITDA $ 46.1 $ 32.0 $ 78.1 $ 42.9 $ 34.3 $ 77.2 Q1 2021 Q2 2021 Q3 2021 Pro forma Pro forma Pro forma Pro forma Pro forma Pro forma Net income from continuing operations 60.4 (3.1) 57.3 50.2 1.4 51.6 33.4 1.5 34.9 Income tax expense 16.3 1.1 17.4 13.8 1.3 15.1 2.0 2.5 4.5 Interest expense 19.3 11.1 30.4 19.5 11.2 30.7 19.0 11.2 30.2 Depreciation and amortization 36.9 17.5 54.4 33.6 17.3 50.9 36.6 17.1 53.7 EBITDA 132.9 26.6 159.5 117.1 31.2 148.3 91.0 32.3 123.3 Special items, before tax 2.4 — 2.4 14.2 — 14.2 19.9 — 19.9 Depreciation included in special items (0.6) — (0.6) 1.4 — 1.4 (0.9) — (0.9) Adjusted EBITDA $ 134.7 $ 26.6 $ 161.3 $ 132.7 $ 31.2 $ 163.9 $ 110.0 $ 32.3 $ 142.3 Q4 2021 YTD 2021 Pro forma Pro forma Pro forma Pro forma Net income from continuing operations 11.2 2.5 13.7 155.2 1.6 156.8 Income tax expense 16.2 (1.9) 14.3 48.3 3.7 52.0 Interest expense 17.5 11.1 28.6 75.3 44.6 119.9 Depreciation and amortization 37.9 18.9 56.8 145.0 70.8 215.8 EBITDA 82.8 30.6 113.4 423.8 120.7 544.5 Special items, before tax 20.6 — 20.6 57.1 — 57.1 Depreciation included in special items (1.6) — (1.6) (1.7) — (1.7) Adjusted EBITDA $ 101.8 $ 30.6 $ 132.4 $ 479.2 $ 120.7 $ 599.9 3 Q1 2022 Q2 2022 Pro forma Pro forma Pro forma Pro forma Net income from continuing operations 64.7 2.6 67.3 62.8 5.2 68.0 Income tax expense 20.0 1.7 21.7 22.7 1.4 24.1 Interest expense 16.9 11.1 28.0 16.2 11.1 27.3 Depreciation and amortization 37.6 16.6 54.2 36.3 16.6 52.9 EBITDA 139.2 32.0 171.2 138.0 34.3 172.3 Special items, before tax 6.6 — 6.6 0.9 — 0.9 Depreciation included in special items (2.1) — (2.1) (1.1) — (1.1) Adjusted EBITDA $ 143.7 $ 32.0 $ 175.7 $ 137.8 $ 34.3 $ 172.1 Reconciliation of Specialty Engineered Pro Forma Sales Sales 214.7 238.9 231.7 226.3 911.6 243.1 242.3 Pro forma APM 98.9 108.8 93.8 94.9 396.4 94.8 100.5 Pro forma sales $ 313.6 $ 347.7 $ 325.5 $ 321.2 $ 1,308.0 $ 337.9 $ 342.8 Reconciliation of Avient Pro Forma Sales Sales 826.0 864.5 818.0 807.1 3,315.6 892.2 891.0 Pro forma APM 98.9 108.8 93.8 94.9 396.4 94.8 100.5 Pro forma sales $ 924.9 $ 973.3 $ 911.8 $ 902.0 $ 3,712.0 $ 987.0 $ 991.5 4 IR Slides V17 - 9.26 324pm IR Deck - AVNT-2022.09.27 Pre Release v2
https://www.avient.com/industries/healthcare/medical-devices-equipment/imaging-technology
Medical imaging equipment, from large stationary machines like magnetic resonance imaging (MRI) systems to smaller portable devices such as handheld ultrasound scanners, must be carefully designed to withstand electrical interference, harsh chemicals, excessive ultraviolet (UV) radiation, and various environmental factors. Explore various polymer performance to understand how material selection can prevent cracking and crazing, minimizing disinfectant-related failures in medical devices Learn how chemically resistant Trilliant™ HC thermoplastics and Versaflex™ HC TPEs provide enhanced durability to withstand common hospital cleaners and disinfectants